How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rebamipide-and-esomeprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rebamipide and Esomeprazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rebamipide and Esomeprazole (Rebamipide and Esomeprazole) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucoprotective agent + Proton pump inhibitor combination. Area: Gastroenterology.

marketed Mucoprotective agent + Proton pump inhibitor combination Rebamipide: gastric mucosa protective mechanisms; Esomeprazole: H+/K+-ATPase Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Rebamipide and Esomeprazole (Rebamipide and Esomeprazole) — Otsuka Pharmaceutical, Inc., Philippines. This combination product uses rebamipide to protect and promote gastric mucosa healing while esomeprazole reduces gastric acid secretion to treat acid-related disorders.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rebamipide and Esomeprazole TARGET	Rebamipide and Esomeprazole	Otsuka Pharmaceutical, Inc., Philippines	marketed	Mucoprotective agent + Proton pump inhibitor combination	Rebamipide: gastric mucosa protective mechanisms; Esomeprazole: H+/K+-ATPase
Rebamipide and Omeprazole	Rebamipide and Omeprazole	Otsuka Pakistan Limited	phase 3	Mucoprotective agent + Proton pump inhibitor combination	Rebamipide: gastric mucosa protective pathways; Omeprazole: H+/K+-ATPase (proton pump)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucoprotective agent + Proton pump inhibitor combination class)

Otsuka Pakistan Limited · 1 drug in this class
Otsuka Pharmaceutical, Inc., Philippines · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rebamipide and Esomeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/rebamipide-and-esomeprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab